Navigation Links
Genitourinary in Medical News

Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting

... Annual Meeting in Orlando, Fla. Oral Abstract Session: genitourinary (Prostate) Cancer Abstract Title: "Antitumor Activity of ... principal investigator, chief of the genitourinary Oncology Service and the D. Wayne Calloway ...

Drug shows activity in men with advanced prostate cancer

... who received the drug at higher doses were recently reported at the ASCO genitourinary Cancers Symposium in February 2009 (see abstract: ... encouraging," said Howard Scher, MD, a study co-author and Chief of the genitourinary Oncology Service at MSKCC. "I am looking forward to continuing the study ...

New Prostate Cancer Drug May Hold Promise

... those androgens on the tumor cells, said Dr. Howard I. Scher, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York ... cancer . SOURCES: Howard I. Scher, M.D., chief, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, New York City; ...

Tests Might Diagnose, Predict Prostate Cancer

... developing the disease. Both studies were presented Tuesday at the 2009 genitourinary Cancers Symposium in Orlando, Fla., sponsored by the American Society of ... Memorial Sloan-Kettering Cancer Center, New York City; presentations, 2009 genitourinary Cancers Symposium sponsored by American Society of Clinical Oncology, ...

Hormone Therapy Only Helps Some Older Men With Prostate Cancer

... on the gentleman's health," said Dr. Anthony V. D'Amico, chief of genitourinary oncology at Brigham and Women's Hospital in Boston. His report is ... SOURCES: Anthony V. D'Amico, M.D., chief, genitourinary oncology, Brigham and Women's Hospital, Boston; Durado Brooks, director, ...

Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients

... said lead researcher Dr. Anthony V. D'Amico, chief of the division of genitourinary radiation oncology at Brigham & Women's Hospital and the Dana-Farber ... SOURCES: Anthony V. D'Amico, M.D., Ph.D., chief, division of genitourinary radiation oncology, Brigham & Women's Hospital and Dana-Farber Cancer ...

PSA Testing Still Valuable for Prostate Cancer

... treatment for prostate cancer, said Slovin, an assistant member of the genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center, and an ... for the National Prostate Cancer Coalition, an assistant member of the genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center, and an ...

Blood transfusion study: Less is more

... percent, and blood use among men varied from about 50 percent to 100 percent. Transfusions with donor blood were associated with infections of the genitourinary system, respiratory tract, bloodstream, digestive tract and skin, the study said. The risk of death in the hospital was nearly 5 times greater ...

Combination Therapy Best for Aggressive Prostate Cancer

... supporting this treatment method alone based on survival data from randomized trials is lacking," lead researcher Dr. Anthony D'Amico, chief of genitourinary radiation oncology at Brigham and Women's Hospital in Boston, said in a news release from the hospital. "In order to get the highest cure rate for ...

MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009

... than 43,000 cancer treaters globally and covers all major and smaller oncology areas, including lung cancer, breast cancer, gastrointestinal cancer, genitourinary cancer, gynecological cancer, hematological malignancies, and melanoma. MDOUTLOOK is being launched in other complex diseases, such as Rheumatoid ...

More>>

Genitourinary in Medical Technology

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... Clinic Taussig Cancer Institute, in a poster discussion during the genitourinary Cancer session. The study enrolled a total of 50 patients, of which ... Principal Investigator Nicholas Vogelzang, MD, Professor and Head of the genitourinary Cancer Program at the Nevada Cancer Institute, stated, "perifosine ...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

... - Data presented today at American Society of Clinical Oncology (ASCO) genitourinary Cancers Symposium - MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta ... prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) genitourinary Cancers Symposium in Orlando, FL. AT-101, an oral, pan-Bcl-2 inhibitor ...

Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients

... - Poster Presented at ASCO genitourinary Cancers Satellite Symposium - SOUTH SAN FRANCISCO, Calif., Feb. 15 ... 1 study of picoplatin, the Company's lead product candidate, at the 2008 genitourinary (GU) Cancers Symposium, a meeting of the American Society of Clinical ...

Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival

... Presented at American Society of Clinical Oncology's genitourinary Symposium - SEATTLE and SAN FRANCISCO, Feb. 14 /PRNewswire-FirstCall/ ... is being presented at the American Society of Clinical Oncology's 2008 genitourinary Symposium in San Francisco. In two Phase 3 trials, D9901 and D9902A, ...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... on average a year or less -- with no approved treatment options," said Howard Scher, M.D., principal investigator of the trial and chief of the genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York. "These findings suggest ...

Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

... with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC) during the American Society of Clinical Oncology (ASCO) 2009 genitourinary Cancers Symposium. Efficacy results to date showed reductions in prostate specific antigen (PSA) levels of at least 50 percent were achieved in 78 ...

Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting

... MDV3100 in patients (pts) with progressive Castration-Resistant Prostate Cancer (CRPC)" by principal investigator, Howard Scher, M.D., chief of the genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York. The ongoing Phase 1-2 ...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

... of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first-line therapy for advanced non-small cell lung cancer (NSCLC) genitourinary -- Guru Sonpavde, M.D., Texas Oncology-Deke Slayton Cancer Center: Phase II study of Azacitidine for castration-resistant prostate cancer ...

Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting

... in Patients with Progressive Castration-Resistant Prostate Cancer (CRPC)" (Abstract #5006) To be presented by: Howard Scher, M.D., chief of the genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York, at approximately 12:15 ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)" (Abstract #5146, genitourinary Cancer Session) -- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on Saturday, May 31, 2008. Clinical and Preclinical Data of ...
Genitourinary in Medical Dictionary

Genitourinary system

... Trauma of the genitourinary system is defined as injury resulting from ... those concerned with reproduction. Also called genitourinary system , urogenital system, or urogenital ... parts of the esophagus and trachea ), and the genitourinary system . ...

Genital

... warts are the most common sexually transmitted infection diagnose d in genitourinary medicine (GUM) clinics. We look at the best ways to prevent infection , ... excretion of urine and those concerned with reproduction. Also called genitourinary system , uro genital system, or uro genital tract. Genital ...

Genital warts

... warts are the most common sexually transmitted infection diagnose d in genitourinary medicine (GUM) clinics. We look at the best ways to prevent infection , ... excretion of urine and those concerned with reproduction. Also called genitourinary system , urogenital system, or urogenital tract. Genital Warts ...

Gland

... s T3 and T4. Common causes include an enlarged prostate gland in older men, sagging pelvic muscle s in older women, and tumor s in the genitourinary organ s of both males and females. Plenaxis (abarelix depot) A peptide antagonist that inhibits the action of gonad otropin-releasing hormone ...

Intestinal obstruction

... stress with or without hepatomegaly or cord compress ion and neurologic deficit or inferior vena cava compress ion and renal ischemia ; or genitourinary obstruction; or gastrointestinal obstruction and ... Fever and headache are other constitutional symptoms. Severe involvement of the rectal ...

Invasive

... any and all treatment options with your healthcare professional. Minimally Invasive Surgical Procedures used to correct disorders of the genitourinary System Programs that treat this condition Center for Bladder Exstrophy Care & Support Group ... Arthroscopy : Less invasive surgery for ...

Ischemia

... pressure point. Such symptoms include respiratory di stress , renal or bowel ischemia , spinal cord compress ion, gastrointestinal or genitourinary obstruction, or coagulopathy. bowel angina , or pain in the abdomen which is worse after meals, or bowel ischemia (decreased blood ...

Nephropathy

... may result in kidney damage. Also called nephropathy . Large birth weight ... [25] Patients with Wilms' tumor and aniridia without genitourinary abnormalities are at lesser risk but should be monitored for nephropathy or renal failure. it is a useful ' first -line treatment for ...

Prostate

... and lung cancer . Common causes include an enlarged prostate gland in older men, sagging pelvic muscle s in older women, and tumor s in the genitourinary organ s of both males and females. Prognosis The projected outcome of a disease ; the life expectancy. PSA ( Prostate -specific antigen ) A ...

Soy

... in abundance), nuts and seeds. An isoflavone found in soy products. Soy isoflavones are being studied to see if they help prevent cancer . genitourinary system (GEN-ih-toe-YOO-rin-air-ee) ... A natural approach to treatment includes taking natural plant oestrogens - called phytoestrogens or ...

More>>

Genitourinary in Biological News

Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test

... K. Oh, M.D., clinical director, Lank Center for genitourinary Oncology, DFCI today presented the data from ... at the American Society for Clinical Oncology's genitourinary Cancers Symposium. The study was co-investigated ... Ross, M.D., attending physician, Lank Center for genitourinary Oncology, DFCI. The PCCTC, a national clinical ...

New drug shows promise in treating drug-resistant prostate cancer

... what Jung described as "the pivotal Phase 3 clinical trials." The results of clinical studies with MDV3100 were described at the 2009 ASCO genitourinary Cancer Symposium in February by the trials' principal investigator, Dr. Howard Scher of Memorial Sloan-Kettering Cancer Center. In general, the drug, ...

UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas'

... cellular processes that take place in external genitalia development, like outgrowth and closure of the urethral tube," Cohn said. "The incidence of genitourinary malformations in humans came as a huge surprise to me. A staggeringly high frequency of one in 250 kids has a urethral tube defect, and that number ...

UCLA/VA partners with ASU to advance biosensor technology for urinary tract infections

... have pioneered treatments for many conditions, including cancers of the prostate, bladder and kidney; kidney stones; pelvic floor disorders; genitourinary tract conditions; incontinence; and sexual dysfunction in men and women. The Biodesign Institute at Arizona State University is focused on ...

More kidney cancer is detected and treated early, yet death rate rises

... are some patients with small kidney tumors for whom surgery is not the best option." Kidney cancer is the third most common malignancy of the genitourinary system (the reproductive system and urinary system). The American Cancer Society estimates there will be about 38,890 new cases of kidney cancer ...
Genitourinary in Biological Technology

Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

... - - Data To Be Presented at ASCO's 2009 genitourinary Cancers Symposium - - Medivation to Host ... investigator of the trial and chief of the genitourinary Oncology Service and the D. Wayne Calloway Chair ... Society of Clinical Oncology's (ASCO) 2009 genitourinary Cancers Symposium in Orlando, Fla. ...

Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

... the American Society of Clinical Oncology's 2009 genitourinary Cancers Symposium - SOUTH SAN FRANCISCO, ... M.D., clinical director of the Lank Center for genitourinary Oncology at the Dana Farber Cancer Institute and ... Society of Clinical Oncology's (ASCO) 2009 genitourinary Cancers Symposium in Orlando, Fla. Picoplatin, ...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

... investigation of the drug in hormone-refractory prostate cancer, a major genitourinary cancer indication in male patients. Abstract selected for presentation is as follows: genitourinary Cancer Sunday, May 31, 2009: # 5103: Expression of LHRH receptors ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... metastatic castration resistant prostate cancer (mCRPC)" (Abstract #5138, genitourinary Cancer - Prostate Session) S. Slovin - General poster from 2:00 p.m. to ... metastatic castration-resistant prostate cancer (mCRPC)" (Abstract #5144, genitourinary Cancer Session) M. Mohebtash - General poster from 2:00 p.m. to 6:00 p.m. ...

OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer

... Data presented at the 2008 genitourinary Cancers Symposium VANCOUVER, Feb. 15 /PRNewswire/ - OncoGenex ... with chemotherapy alone. Phase 2 data were presented today at the 2008 genitourinary Cancers Symposium. OncoGenex and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

... prolonged use of LHRH agonists; these data provide further support to the investigation of AEZS-108 in hormone-refractory prostate cancer, a major genitourinary cancer indication in male patients." Results LHRH receptor expression was demonstrated in more than 95% of 130 prostate cancer specimens ...

The Arcas Group Appoints Executive Vice President

... treaters in North America and Europe and covers all major and smaller oncology areas, including lung cancer, breast cancer, gastrointestinal cancer, genitourinary cancer, hematological malignancies and melanoma. MDOUTLOOK will be launched shortly in other complex diseases, such as Ophthalmology, Parkinson's ...

Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009

... presented at international cancer symposium In February 2009, data on PROSTVAC(TM) were presented at the international cancer congress, 2009 genitourinary Cancers Symposium in Orlando, Florida. The data from three different studies once again confirm the excellent safety and efficacy results previously ...

Bavarian Nordic Publishes its Annual Results 2008

... - further data presented In February 2009, the first detailed data on PROSTVAC(TM) were presented at the international cancer congress, 2009 genitourinary Cancers Symposium in Orlando, Florida. The data from three different studies once again confirms the excellent safety and efficacy results ...

Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update

... trial in patients with castration-resistant prostate cancer (CRPC). Presented data from our Phase 1-2 clinical trial at ASCO's 2009 genitourinary Cancers Symposium showing that MDV3100 consistently demonstrated encouraging anti-tumor activity across dose levels, endpoints and in both pre- and ...
Other Contents
(Date:8/20/2014)... 2014 The National Association of ... million Science Education Partnership Award (SEPA) grant from ... collaborative project with the Hispanic Communications Network (HCN) ... This collaborative NIH R25 program has been established ... diversity among health professionals by recruiting and interviewing ...
(Date:8/20/2014)... August 20, 2014 New Jersey’s Medical ... of an estimated tens of thousands of patients in ... Bill A3525—a bill that would expand the list of ... own cannabis—earlier this summer by State Assemblywoman Linda Stender, ... quality marijuana is growing. , To help fill the ...
(Date:8/20/2014)... Verndale is pleased to announce their ... exclusive list ranking the fastest-growing private companies in America. ... their yearly percentage revenue growth over a three-year period. ... Inc. 5000 list where it ranked number 2,855. , ... clients a wide range of digital marketing services including ...
(Date:8/20/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... System in Hermiston, Ore. The top executive search ... has recently placed more than 900 healthcare executives into ... a progressive, not-for-profit healthcare organization serving a population of ...
(Date:8/20/2014)... 2014 Biosimilars, which are similar ... through an abbreviated process, could reap billions in ... Information Services, Inc.’s (AIS) Specialty Pharmacy News offers ... the Food and Drug Administration’s (FDA) recent acceptance ... approval. , Drugmaker Sandoz said July 24 that ...
Breaking Medicine News(10 mins):Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3
(Date:8/20/2014)... grows to about 4,000 members, it triggers an important ... a special type of comb used for rearing male ... Department of Neurobiology and Behaviour at Cornell University, led ... of honeybee colonies. The results are published in Springer,s ... , Reproduction isn,t always a honeybee colony,s top ...
(Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
(Date:8/19/2014)... in German . ... sources. If a large amount of electricity is to be ... will have to be stored during productive periods so that ... are far from adequate for the purpose. Science and industry ... lies on battery systems that used to be too expensive ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
Other TagsOther Tags